公开(公告)号：US20220204518A1

公开(公告)日：2022-06-30

申请号：US17606121

申请日：2020-04-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao ZHANG ,  Jian DING ,  Hua XIE ,  Zilan SONG ,  Yu XUE ,  Li XING ,  Linjiang TONG ,  Meiyu GENG

IPC: C07D487/14 ,  A61P35/00

Abstract: The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.

公开(公告)号：US20170066723A1

公开(公告)日：2017-03-09

申请号：US15120771

申请日：2015-02-15

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Wenhu DUAN ,  Jian DING ,  Yongcong LV ,  Hua XIE

IPC: C07D231/56 ,  C07D261/20 ,  C07D413/12 ,  C07D401/12 ,  C07D491/048 ,  C07D495/04

CPC classification number: C07D231/56 ,  C07D261/20 ,  C07D401/12 ,  C07D413/12 ,  C07D491/048 ,  C07D495/04

Abstract: The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.

Abstract translation: 本发明涉及由式（I）表示的结构的萘酰胺化合物，其药物盐，前药和水合物或溶剂化物，还涉及制备该化合物的方法，包含该化合物的药物组合物及其用途为 蛋白酪氨酸激酶抑制剂，特别是作为VEGFR-2抑制剂，在制备用于预防和治疗与异常血管生成有关的疾病的药物中。

公开(公告)号：US20230382871A1

公开(公告)日：2023-11-30

申请号：US18027759

申请日：2021-09-22

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Jian DING ,  Wenhu DUAN ,  Hua XIE ,  Meiyu GENG ,  Caixia WANG ,  Zhengsheng ZHAN ,  Na GAO ,  Yang ZHANG

IPC: C07D231/56 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07D231/56 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505

Abstract: Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.